









Markets
/
Stocks
/
nasdaq-capr
/

Capricor Therapeutics Inc

CAPR

5.930USD

-0.350-5.57%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

271.07MMarket Cap

LossP/E TTM



Capricor Therapeutics Inc

5.930

-0.350-5.57%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Capricor Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Capricor Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

162 / 407

Overall Ranking

292 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

20.600

Target Price

+228.03%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Capricor Therapeutics Inc Highlights

StrengthsRisks

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 772.85% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 22.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 22.27M.

Overvalued

The company’s latest PE is -3.72, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.82M shares, decreasing 43.90% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 3.04K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.09.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 5.67, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 135.56%.

Score

Industry at a Glance

Previous score

5.67

Change



Financials

3.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.68

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Capricor Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 5.77, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.72, which is -36.85% below the recent high of -2.35 and -475.45% above the recent low of -21.43.

Score

Industry at a Glance

Previous score

5.77

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 162/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Capricor Therapeutics Inc is 21.50, with a high of 29.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

20.600

Target Price

+228.03%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Capricor Therapeutics Inc

CAPR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.36, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 6.76 and the support level at 5.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.74

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Sell

RSI(14)

41.782

Neutral

STOCH(KDJ)(9,3,3)

11.915

Oversold

ATR(14)

0.371

High Vlolatility

CCI(14)

-124.266

Sell

Williams %R

97.458

Oversold

TRIX(12,20)

-0.453

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.112

Sell

MA10

6.256

Sell

MA20

6.320

Sell

MA50

6.573

Sell

MA100

7.367

Sell

MA200

9.749

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 30.24%, representing a quarter-over-quarter decrease of 47.93%. The largest institutional shareholder is The Vanguard, holding a total of 2.21M shares, representing 4.83% of shares outstanding, with 3.02% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nippon Shinyaku Co Ltd

7.09M

+230.41%

BlackRock Institutional Trust Company, N.A.

2.73M

+1.28%

The Vanguard Group, Inc.

Star Investors

2.30M

+1.82%

State Street Investment Management (US)

1.47M

-20.41%

Geode Capital Management, L.L.C.

963.08K

+6.85%

UBS Financial Services, Inc.

546.02K

+38.82%

Morgan Stanley & Co. LLC

463.03K

-37.01%

Pier Capital, LLC

367.72K

+3.82%

Northern Trust Investments, Inc.

358.65K

-2.56%

Black Diamond Financial, LLC

277.74K

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.65, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.